ESMO Clinical Practice Guidelines
Establishing the highest standards of clinical practice is a collective effort of the whole oncology community. The ESMO Clinical Practice Guidelines, prepared and reviewed by leading experts, help you provide patients with the best care options.
Cancer research is constantly advancing. Evidence-based medicine transfers the results of that research into new standards and methods for clinical practice. Thanks to ESMO’s regularly updated Clinical Practice Guidelines the decisions you make every day are supported by the informed consensus of the leading experts in our profession.
New and Updated ESMO Clinical Practice Guidelines in 2017!
In addition to three new titles:
- EANO and ESMO Guidelines on Leptomeningeal Metastasis from Solid Tumours
- Infusion Reactions
- Toxicities from Immunotherapy
we have also updated the following six guidelines:
ESMO Clinical Practice Guidelines News
Keep up to date with news about ESMO guidelines, including the latest CPG publications, updated recommendations, algorithms, pocket guidelines and MCBS grading
of ESMO Clinical Practice Guidelines NewsESMO Clinical Practice Guidelines: Breast Cancer
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC3) • Primary Breast Cancer • 2nd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC2) • BRCA in Breast Cancer
of ESMO Clinical Practice Guidelines: Breast CancerESMO Clinical Practice Guidelines: Cancers of Unknown Primary Site
Cancers of Unknown Primary Site
of ESMO Clinical Practice Guidelines: Cancers of Unknown Primary SiteESMO Clinical Practice Guidelines: Endocrine and Neuroendocrine Cancers
Neuroendocrine Bronchial and Thymic Tumours • Neuroendocrine Gastroenteropancreatic Tumours
of ESMO Clinical Practice Guidelines: Endocrine and Neuroendocrine CancersESMO Clinical Practice Guidelines: Gastrointestinal Cancers
Rectal Cancer • Biliary cancer • Gastric cancer • Oesophageal cancer • Cancer of the pancreas • Metastatic colorectal cancer • Anal cancer • Early colon cancer • Familial risk colorectal cancer • Hepatocellular carcinoma
of ESMO Clinical Practice Guidelines: Gastrointestinal CancersESMO Clinical Practice Guidelines: Genitourinary Cancers
Cancer of the Prostate • Bladder Cancer • Renal Cell Carcinoma • Penile Carcinoma • Testicular Seminoma and Non-Seminoma
of ESMO Clinical Practice Guidelines: Genitourinary CancersESMO Clinical Practice Guidelines: Gynaecological Cancers
Cervical cancer • Endometrial cancer • Gestational trophoblastic disease • Newly diagnosed and relapsed epithelial ovarian carcinoma • Non-epithelial ovarian cancer
of ESMO Clinical Practice Guidelines: Gynaecological CancersESMO Clinical Practice Guidelines: Haematological Malignancies
Chronic myeloid leukaemia • Newly diagnosed and relapsed mantle cell lymphoma • Multiple myeloma • Newly diagnosed and relapsed follicular lymphoma • Extranodal diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma • Acute lymphoblastic leukaemia • Peripheral T-cell lymphomas • Diffuse large B cell lymphoma • Chronic lymphocytic leukaemia • Hairy cell leukaemia • Philadelphia chromosome-negative chronic myeloproliferative neoplasms • Myelodysplastic syndromes • Hodgkin's lymphoma • Primary cutaneous lymphoma • Acute myeloblastic leukaemia in adult patients • Waldenstrom's macroglobulinaemia • Gastric marginal zone lymphoma of MALT type
of ESMO Clinical Practice Guidelines: Haematological MalignanciesESMO Clinical Practice Guidelines: Head and Neck Cancers
Nasopharyngeal Cancer • Squamous-Cell Carcinoma of the Head and Neck
of ESMO Clinical Practice Guidelines: Head and Neck CancersESMO Clinical Practice Guidelines: Hereditary Syndromes
Prevention and Screening in BRCA Mutation Carriers and Other Breast/Ovarian Hereditary Cancer Syndromes
of ESMO Clinical Practice Guidelines: Hereditary SyndromesESMO Clinical Practice Guidelines: Lung and Chest Tumours
Early and locally advanced non-small-cell lung cancer • Metastatic non-small-cell lung cancer • Thymic epithelial tumours • Malignant pleural mesothelioma • Small-cell lung cancer
of ESMO Clinical Practice Guidelines: Lung and Chest TumoursESMO Clinical Practice Guidelines: Melanoma
Cutaneous Melanoma
of ESMO Clinical Practice Guidelines: MelanomaESMO Clinical Practice Guidelines: Neuro-Oncology
EANO and ESMO guidelines on leptomeningeal metastasis from solid tumours • High-grade malignant glioma
of ESMO Clinical Practice Guidelines: Neuro-OncologyESMO Clinical Practice Guidelines: Sarcoma and GIST
Soft Tissue and Visceral Sarcomas • Bone Sarcomas • Gastrointestinal Stromal Tumours
of ESMO Clinical Practice Guidelines: Sarcoma and GISTESMO Clinical Practice Guidelines: Supportive and Palliative Care
Management of infusion reactions to systemic anticancer therapy • Management of toxicities from immunotherapy • Management of febrile neutropaenia • MASCC and ESMO consensus guidelines for the prevention of chemotherapy and radiotherapy-induced nausea and vomiting • Treatment of dyspnoea in advanced cancer patients • Central venous access in oncology • Management of oral and gastrointestinal mucosal injury • Management of refractory symptoms at the end of life and the use of palliative sedation • Advanced care planning in palliative care • Bone health in cancer patients • Cancer, fertility and pregnancy • Management of chemotherapy extravasation • Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy • Management of cancer pain • Management of venous thromboembolism in cancer patients • Prevention of chemotherapy and radiotherapy-induced nausea • Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients • Haematopoietic growth factors
of ESMO Clinical Practice Guidelines: Supportive and Palliative Care